Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
-
US midterms begin with chaos over mail-voting crackdown
-
Argentina ordered to return Nazi-looted painting to Jewish collector's heir
-
Russell tops second practice to beat Ferrari and Antonelli in Italy
-
Director Maggie Gyllenhaal ditched AI for Marilyn Monroe film
-
'I love the players we have', insists Arsenal boss Arteta
-
'Winner' Fernandez fundamental to Maresca's Man City rebuild
-
Jury resumes deliberations in case of US mother who killed her three children
-
Song Yadong looks to become China's first male UFC champion after home victory
-
Farage's Reform UK meets under cloud of new donation scandal
-
Russia hits SBU headquarters, Ukraine says security chief's office was target
-
Man Utd in 'good place' despite imperfect squad, says Carrick
-
US shows strong job growth in August in boon to Trump
-
Le Pen party sparks furore with 'turn off tap' to Ukraine call
-
Alonso urges Chelsea to 'move forward' after Fernandez's exit
-
Emery says Madjo's time will come after Villa Euro exclusion
-
US safety regulator probes Tesla's Cybercab
-
Workers reeling after VW cuts open door to factory closures
-
Voting begins in crucial US midterm elections
-
Liquid Mercury Announces Initial Closing of ACQUA1 Offering
-
US shows strong job growth in August in boon to Trump ahead of midterms
-
Stocks slip as robust US jobs data stokes rate hike chances
-
US diesel price hits new high on Iran war, squeezing voters
-
France to abandon 'distorted' Mercator map projection: minister
-
Swiss far-right extremists go on trial amid protests
-
Celtic, Rangers away fans shut out from Old Firm derbies
-
Record European fires burn over 500,000 hectares over summer
-
Cadillac enjoying 'very respectable' first season, says team boss
-
Former world triathlon champion Jonny Brownlee retires from professional running
-
Five acquitted over deadly 2017 landslide in Swiss Alps
-
'No room for mistakes' scaling Everest in Venice documentary
-
France unveils 1 bn euro farm aid package after climate-hit summer
-
Rubio to visit Trump-friendly allies Colombia, Ecuador, Peru: State Dept
-
Irish heroine Taylor eyes fairytale finish to trailblazing ring career
-
Indonesia steps up wildfire fight that sparked hazardous haze
-
Weather and war push up food prices in August: FAO
-
Leclerc on top as Ferrari take 1-2 in Monza opening practice
-
'No longer safe': Nepal flood survivors left landless
-
Malaysia declares haze emergency in Sarawak state on Borneo
-
Stocks mixed before US jobs data, oil dips
-
East German refinery adjusts to life without Russian oil
-
Optimised urinals and buried underwear at 2026 Ig Nobels
-
Song Yadong looks to become China's first UFC champion after home victory
-
German factory orders rise again in latest recovery sign
-
India's Mandhana becomes top run-scorer in women's cricket
-
Nepal's 'Himalayan tsunami': what we know
-
IUX Announces Two New Podcast Series: IUX Market Trendline and The Market Journey
-
SPAYZ.io brings Africa’s payment growth story to Forex Expo Dubai 2026
-
Brussels Diamond League finals Day 2 - four events to watch
-
Zelensky slams his security services for 'unacceptable' shootout
-
Looming far-right win in Germany sparks security worries
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
J.Oliveira--AMWN
